Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2022

View Archived Issues

Researchers present CX-10759 anti-IgE antibody for hypersensitivity

RUNX1 targeting shows promise for treating aggressive PDAC

Sitryx Therapeutics describes nuclear factor erythroid 2-related factor 2 activators

New SLC10A2/SLC10A1 inhibitors identified at Albireo

Ruhr University Bochum presents new compounds for treating axonal damage

Roche divulges new TLR7/8/9 antagonists

Eoetvoes Lorand Tudomanyegyetem, Semmelweis University patent imipridone derivatives

Immunotherapies targeting WT137-45 may avoid acute myeloid leukemia immune evasion

BBP-671 restores brain glutamate/glutamine levels in preclinical model of coenzyme A deficiency

Novel propolis-derived CREB/CRTC2 inhibitor ameliorates metabolic syndrome in obese mice

NTLA-2002 shows promising preclinical results in a partial hepatectomy-induced HAE model

RedCloud cleared to enter clinic with next-generation EGFR inhibitor H-002 for NSCLC

Novel IL-33-dependent mouse model of eosinophilic esophagitis

Adagene and Sanofi collaborate on masked monoclonal and bispecific antibodies for immuno-oncology

PMN-310 shows cognitive benefit in mouse model of Alzheimer's disease

9 Meters collaborates with NYU Langone Health to evaluate NM-102 for autoimmune disorder

Intranasal COVID-19 booster BW-1019 provides protection and boosts immune response in hamsters

Infection in thymus causes autoimmunity in stomach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...